⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYMR News
Kymera Therapeutics, Inc. Common Stock
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
prnewswire.com
KYMR
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
globenewswire.com
KYMR
Form 8-K
sec.gov
KYMR
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
globenewswire.com
KYMR
Form 8-K
sec.gov
KYMR
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
globenewswire.com
KYMR
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
globenewswire.com
KYMR
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
globenewswire.com
KYMR
Form 8-K
sec.gov
KYMR
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
globenewswire.com
KYMR